文献速递乳腺癌

维利帕尼单药维持治疗用于胚系BRCA突变晚期乳腺癌患者:III期BROCADE3试验探索性分析结果

Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
PubMed 文献 · Ann Oncol · 2021-11-30

BROCADE3试验中,在卡铂/紫杉醇基础上加用维利帕尼可改善胚系BRCA1/2突变、HER2阴性晚期乳腺癌患者的无进展生存期(HR 0.71,95%CI 0.57-0.88;P=0.002)。本次报告在进展前停用卡铂和紫杉醇、转为盲法维利帕尼/安慰剂单药维持治疗的患者亚组分析结果。

要点

  • 维利帕尼联合卡铂/紫杉醇较安慰剂联合方案改善PFS(HR 0.71,95%CI 0.57-0.88;P=0.002)。
  • 盲法单药维持亚组中,研究者评估的中位PFS从随机化起维利帕尼组25.7个月 vs 安慰剂组14.6个月。
  • 单药维持期任何级别不良事件以胃肠道为主,≥3级最常见为中性粒细胞减少和贫血(维利帕尼组各4%;安慰剂组分别为5%和2%)。

核心结论

  • 维利帕尼维持单药治疗具有可耐受的安全性特征,并可能延长联合化疗后的PFS。

研究设计与样本

  • III期BROCADE3试验的探索性分析,患者按2:1随机分配至维利帕尼+卡铂/紫杉醇组或安慰剂+卡铂/紫杉醇组。
  • 维利帕尼120 mg每日两次于第-2至5天给药,卡铂(曲线下面积6 mg/ml)第1天给药,紫杉醇(80 mg/m2)第1、8、15天给药,21天为一周期。
  • 在进展前停用卡铂和紫杉醇的患者接受盲法研究药物单药治疗,剂量增至300-400 mg每日两次持续给药。
  • 共136/337例随机分配至维利帕尼+卡铂/紫杉醇组的患者和58/172例随机分配至安慰剂+卡铂/紫杉醇组的患者在进展前停用卡铂和紫杉醇并继续盲法维利帕尼或安慰剂单药治疗。
  • 采用包含所有患者数据的时间依赖性Cox模型评估联合治疗阶段和单药治疗阶段的治疗效果。

主要发现

  • 在盲法单药维持亚组中,研究者评估的中位PFS从随机化起维利帕尼组为25.7个月 vs 安慰剂组为14.6个月。
  • 时间依赖性Cox模型的风险比在联合治疗阶段和单药治疗阶段均支持维利帕尼。
  • 单药维持阶段任何级别不良事件主要为胃肠道事件。
  • ≥3级不良事件最常见为中性粒细胞减少和贫血(维利帕尼组各4%;安慰剂组分别为5%和2%)。

关键数值与推荐

  • BROCADE3试验中,维利帕尼联合卡铂/紫杉醇较安慰剂联合方案改善PFS(HR 0.71,95%CI 0.57-0.88;P=0.002)。
  • 盲法单药维持亚组中,研究者评估的中位PFS从随机化起维利帕尼组25.7个月 vs 安慰剂组14.6个月。
  • ≥3级中性粒细胞减少发生率维利帕尼组4% vs 安慰剂组5%;≥3级贫血发生率维利帕尼组4% vs 安慰剂组2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the BROCADE3 trial, addition of the poly(ADP-ribose) polymerase inhibitor, veliparib, to carboplatin/paclitaxel improved progression-free survival (PFS) (hazard ratio 0.71, 95% confidence interval 0.57-0.88; P = 0.002) in patients with advanced human epidermal growth factor receptor 2-negative, germline BRCA1/2-mutated breast cancer. A subset of patients discontinued both carboplatin and paclitaxel before progression and continued on veliparib/placebo maintenance monotherapy until progression. Analyses in this patient subgroup are reported. PATIENTS AND METHODS: Patients were randomized 2 : 1 to veliparib plus carboplatin/paclitaxel or placebo plus carboplatin/paclitaxel. Veliparib (120 mg twice daily) or placebo was given on days -2 to 5, carboplatin (area under the curve 6 mg/ml) on day 1, and paclitaxel (80 mg/m2) on days 1, 8, and 15 of 21-day cycles. Patients who discontinued both carboplatin and paclitaxel before progression received blinded study drug monotherapy at an increased dose of 300-400 mg twice daily continuously. PFS was the primary endpoint. Exploratory analyses were carried out in the subgroup of patients who received blinded study drug as monotherapy. A time-varying Cox model including data from all patients was also used to evaluate treatment effect in the combination and monotherapy phases. RESULTS: A total of 136 of 337 patients randomized to veliparib plus carboplatin/paclitaxel and 58/172 patients randomized to placebo plus carboplatin/paclitaxel discontinued both carboplatin and paclitaxel before progression and continued on blinded veliparib or placebo monotherapy. In this blinded monotherapy subgroup, investigator-assessed median PFS from randomization was 25.7 months with veliparib versus 14.6 months with placebo. Hazard ratios from a time-varying Cox model favored veliparib during both combination therapy and monotherapy. Any-grade adverse events occurring in the monotherapy phase were primarily gastrointestinal. The most common grade ≥3 adverse events were neutropenia and anemia (4% each with veliparib; 5% and 2%, respectively, with placebo). CONCLUSIONS: Veliparib maintenance monotherapy had a tolerable safety profile and may extend PFS following combination chemotherapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Han HS, Arun BK, Kaufman B, et al. Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial. Ann Oncol. 2021. PMID: 34861374. doi:10.1016/j.annonc.2021.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。